Successful Treatment of Notalgia Paresthetica With Botulinum Toxin Type A

Weinfeld, Pamela Kirschner

doi:10.1001/archderm.143.8.980

Cited by 82 publications

(50 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, targeting these SNARE proteins should break the crosstalk link between sensory neurons and skin cells. In this perspective, SNARE‐inactivating agents, such as botulinum neurotoxins, have shown promising in certain itchy diseases which include lichen simplex chronicus, psoriasis and rosacea, meralgia paresthetica, and post‐burn (Akhtar & Brooks, ; Boozalis, Sheu, Selph, & Kwatra, ; Heckmann, Heyer, Brunner, & Plewig, ; Perez‐Perez et al, ; Salardini, Richardson, & Jabbari, ; Wallengren & Bartosik, ; Weinfeld, ; Zanchi et al, ). Altogether, these findings highlight the importance of SNARE as a therapeutic target in the treatment of chronic itch diseases.…”

Section: Potential Therapeutic Targets For Bnp Signalling In Itchmentioning

confidence: 99%

Interventions in the B‐type natriuretic peptide signalling pathway as a means of controlling chronic itch

Meng

Chen

Wang

2020

British J Pharmacology

View full text Add to dashboard Cite

Chronic itch poses major health care and economic burdens worldwide. In 2013, B‐type natriuretic peptide (BNP) was identified as an itch‐selective neuropeptide and shown to be both necessary and sufficient to produce itch behaviour in mice. Since then, mechanistic studies of itch have increased, not only at central levels of the spinal relay of itch signalling but also in the periphery and skin. In this review, we have critically analysed recent findings from complementary pharmacological and physiological approaches, combined with genetic strategies to examine the role of BNP in itch transduction and modulation of other pruritic proteins. Additionally, potential targets and possible strategies against BNP signalling are discussed for developing novel therapeutics in itch. Overall, we aim to provide insights into drug development by altering BNP signalling to modulate disease symptoms in chronic itch, including conditions for which no approved treatment exists.

show abstract

Section: Potential Therapeutic Targets For Bnp Signalling In Itchmentioning

confidence: 99%

Interventions in the B‐type natriuretic peptide signalling pathway as a means of controlling chronic itch

Meng

Chen

Wang

2020

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…NP is clinically defined by a brownish patch in the affected area that is constantly scratched; NP mainly occurs in older patients or is linked with musculoskeletal compression of spinal nerves [73] . The first 2 cases of NP treated with botulinum toxin were described in 2007 [74] . In 2010, Wallengren and Bartosik [75] treated 6 patients affected by NP or neuropathic pruritus with a small improvement.…”

Section: Notalgia Parestheticamentioning

confidence: 99%

Botulinum Toxin Off-Label Use in Dermatology: A Review

Campanati

Martina

Giuliodori

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

focal hyperhidrosis, aesthetic medicine and neurological conditions with a strong efficacy and safety profile [1][2][3][4][5][6][7] . The enormous therapeutic potential of this drug contributed to a number of broad applications, especially in dermatological diseases. A large number of these indications are still lacking shared, approved protocols for dilution, doses, and timing of follow-up and retreatment. Also the injection techniques are still debated, depending on the operator's experience, angle of injection and depth. We have previously published a novel injection approach consisting in a needle adaptor that ensures a uniform administration of the toxin [3] . The aim of this review was to collect and analyze the published data concerning the most relevant off-label indications of BoNT-A. MethodsA PubMed search from 1950 to July 2016 was performed to identify any reports on the use of botulinum toxin in off-label indications concerning dermatology. We detected these articles using the terms "botulinum toxin dermatology," "botulinum toxin treatment," "botulinum toxin off-label," and meshed with a secondary search of studies pertaining to each indication. Only studies in English were reviewed. All studies that met the criteria were included and summarized in this review. KeywordsBotulinum toxin · Off-label therapy · Keloids · Hidradenitis suppurativa · Folds dermatitis Abstract Background: Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum which causes a flaccid muscle paralysis. It is currently used for aesthetic treatments and in the focal hyperhidrosis. Recently, botulinum toxin has also been used experimentally in many other dermatological conditions with good results. Objective: To review and analyze the possible botulinum toxin off-label applications published. Methods: A retrospective review of the published data was conducted. Conclusions: this potent drug can lead to several off-label indications of interest for dermatologists. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and dose protocols.

show abstract

“…Other treatments that have been tried include topical capsaicin [11], cutaneous botulinum toxin type A injections [12], local nerve block [13], gabapentin [14], oxcarbazepine [15], and surgical decompression of the nerve [8]. These therapies have shown varied improvement of symptoms, may be expensive, invasive or require continued long-term use, and in some cases have undesirable side effects (Table 1).…”

Section: Commentmentioning

confidence: 99%

Notalgia paresthetica: the unreachable itch

Ellis

2013

Dermatol Pract Concept

View full text Add to dashboard Cite

Background:Notalgia paresthetica (NP) is a very common, under-recognized condition characterized by pruritus in a unilateral, dermatomal distribution in the mid-back. Chronic pruritus is sometimes accompanied by pain, paresthesias, or altered sensation to touch.Objectives:To review the current literature with regards to the cause of NP and its most appropriate treatment.Methods:Comprehensive literature review using PubMed to inspect the available data on NP.Results:The most likely cause of NP is cutaneous nerve damage. Many therapies have been tried in the treatment of NP, mostly in small case studies.Conclusions:The published cases and studies suggest symptoms of NP are due to a cutaneous sensory neuropathy. Treatments addressing the condition as such are more successful than traditional itch therapies. In many cases, a simple explanation for the persistent pruritus is satisfactory for patients. For very distressing cases, therapy should address the condition as a benign sensory neuropathy. Further studies are needed to evaluate which treatments have the greatest potential for providing symptom relief.

show abstract

Successful Treatment of Notalgia Paresthetica With Botulinum Toxin Type A

Cited by 82 publications

References 13 publications

Interventions in the B‐type natriuretic peptide signalling pathway as a means of controlling chronic itch

Interventions in the B‐type natriuretic peptide signalling pathway as a means of controlling chronic itch

Botulinum Toxin Off-Label Use in Dermatology: A Review

Notalgia paresthetica: the unreachable itch

Contact Info

Product

Resources

About